27. Anhang – Cervical Carcinoma
Table 15: Übersicht der TNM-Kategorien/ FIGO-Stadien (modifiziert 2021)
|
TNM categories |
FIGO- |
Definition |
FIGO Stages (2018) |
Definition |
|
TX |
- |
Primary tumor cannot be assessed |
- |
|
|
0 |
- |
No evidence of primary tumor |
- |
|
|
Tis |
- ¹ |
Carcinoma in situ (preinvasive carcinoma; adenocarcinoma in situ, stratified mucin-producing lesion; SIMLE) |
- ¹ |
- |
|
1 |
I |
Tumor confined to the cervix |
I |
Tumor confined to the cervix |
|
T1a |
IA |
Invasive carcinoma diagnosed only by microscopy. Stromal invasion with a maximum depth of 5.0 mm, with a horizontal spread of 7.0 mm or less |
IA |
Invasive carcinoma diagnosed only by microscopy. Stromal invasion to a maximum depth of 5.0 mm ² |
|
T1a1 |
IA1 |
Stromal invasion of ≤ 3.0 mm in depth and ≤ 7.0 mm in horizontal spread |
IA1 |
Stromal invasion of ≤ 3.0 mm in depth² |
|
T1a2 |
IA2 |
Stromal invasion of > 3.0 mm and ≤ 5.0 mm with a horizontal spread of 7.0 mm or less |
IA2 |
Stromal invasion of more than 3.0 mm but no more ≤ 5.0 mm ² |
|
IB |
(Macroscopically) visible lesion, confined to the cervix, or microscopic lesion > T1a2 / IA2 |
IB |
Clinically (macroscopically) visible lesion, confined to the cervix, or microscopic lesion > T1a2 / IA2 |
|
|
T1b1 |
IB1 |
Clinically (macroscopically) visible lesion, ≤ 4.0 cm in largest extent |
IB1 |
Clinically (macroscopically) visible lesion, ≤ 2.0 cm in largest extent |
|
T1b2 |
IB2 |
Clinically (macroscopically) visible lesion, > 4.0 cm in largest extent |
IB2 |
Clinically (macroscopically) visible lesion, > 2.0 cm but ≤ 4.0cm in largest extent |
|
Tb3 |
- |
- |
IB3 |
(Macroscopically) visible lesion, more than 4.0 cm in largest extent |
|
II |
Tumor invading beyond the uterus, but not as far as the pelvic wall and not to the lower third of the vagina |
II |
Tumor invading beyond the uterus, but not as far as the pelvic wall and not to the lower third of the vagina |
|
|
T2a |
IIA |
Tumor with spread into the vagina (proximal and/or middle third), but without invasion of the parametrium |
IIA |
Tumor with spread into the vagina (proximal and/or middle third), but without invasion of the parametrium |
|
T2a1 |
IIA1 |
Clinically (macroscopically) visible lesion ≤ 4.0 cm at largest extent |
IIA1 |
Clinically (macroscopically) visible lesion ≤ 4.0 cm at largest extent |
|
T2a2 |
IIA2 |
Clinically (macroscopically) visible lesion > 4.0 cm at largest extent |
IIA2 |
Clinically (macroscopically) visible lesion > 4.0 cm at largest extent |
|
T2b |
IIB |
Tumor with invasion of the parametrium, but not as far as the pelvic wall |
IIB |
Tumor with invasion of the parametrium, but not as far as the pelvic wall |
|
T3 |
III |
Tumor extends to the pelvic wall and/or involves the lower third of the vagina and/or causes hydronephrosis or nonfunctional kidney |
III |
Tumor extends to the pelvic wall and/or involves the lower third of the vagina and/or causes hydronephrosis or nonfunctional kidney |
|
T3a |
IIIA |
Tumor involves the lower third of the vagina, with no extension to the pelvic wall |
IIIA |
Tumor involves the lower third of the vagina, with no extension to the pelvic wall |
|
T3b |
IIIB |
Tumor extends to the pelvic wall and/or causes hydronephrosis or nonfunctional kidney |
IIIB |
Tumor extends to the pelvic wall and/or causes hydronephrosis or nonfunctional kidney |
|
pN1 or pM1 |
IVa |
Metastases in the pelvic and/or para-aortic lymph nodes, irrespective of tumor size and extent |
IIIC |
Metastases in the pelvic and/or para-aortic lymph nodes, irrespective of tumor size and extent |
|
pN1 |
IVa |
Metastases only in pelvic lymph nodes |
IIIC1 |
Metastases only in pelvic lymph nodes⁴ |
|
pM1 |
IVa |
Metastases in para-aortic lymph nodes (independently of whether or not pelvic lymph nodes are involved) |
IIIC2 |
Metastases in para-aortic lymph nodes (independently of whether or not pelvic lymph nodes are involved)⁴ |
|
T4 |
IV |
Tumor invades the mucosa of the bladder or rectum or extends beyond the boundary of the lesser pelvis |
IV |
Tumor invades the mucosa of the bladder or rectum or extends beyond the boundary of the lesser pelvis |
|
T4 |
IVa |
Tumor invades the mucosa of the bladder or rectum or extends beyond the boundary of the lesser pelvis |
IVa |
Spread into organs of the lesser pelvis |
|
M1 |
IVb |
Distant metastases, including metastases in para-aortic lymph nodes |
IVb |
Distant metastases |
N classification of regional lymph nodes (pelvic):
NX = regional lymph nodes cannot be assessed
N0 = No regional lymph node metastases
N1 = Regional lymph node metastases
M classification of distant metastases (including para-aortic lymph nodes):
cM0 = No clinical evidence of distant metastases
cM1 = Clinical evidence of distant metastases
pM1 = Histological confirmation of distant metastases
pM0 = Histologically confirmed distant metastases
Lymphatic invasion (L-status):
LX = Invasion of lymphatic vessels cannot be assessed
L0 = No lymphatic invasion
L1 = Evidence of lymphatic invasion
Vascular invasion (V status):
VX = Vascular invasion cannot be assessed
V0 = No vascular invasion
V1 = Evidence of vascular invasion
Invasion of the perineural sheaths (Pn status):
PnX = Perineural invasion cannot be assessed
Pn0 = No perineural invasion
Pn1 = Evidence of perineural invasion
- Carcinoma in situ is not included in the respective FIGO classification, but is anchored in the TNM classification.
- Horizontal extension is no longer relevant for staging in the 2018 FIGO classification. However, no rationale is given for this by FIGO, nor are any relevant studies cited.
- In the 2018 FIGO classification, para-aortic lymph nodes are now defined as regional lymph nodes; this proposal is also followed in the revised reprint of the TNM classification [868].
- It was suggested by FIGO in 2019 that adding the notation “r” (imaging) and “p” (pathology) would indicate the method by which the finding was established.
Table 16: Übersicht der UICC-Stadien (geprüft 2021)
|
UICC stage |
Corresponding TNM categories |
||
|
0 |
Tis |
N0 |
M0 |
|
IA |
T1a |
N0 |
M0 |
|
IA1 |
T1a1 |
N0 |
M0 |
|
IA2 |
T1a2 |
N0 |
M0 |
|
IB |
T1b |
N0 |
M0 |
|
IB1 |
T1b1 |
N0 |
M0 |
|
IB2 |
T1b2 |
N0 |
M0 |
|
II |
T2 |
N0 |
M0 |
|
IIA |
T2a |
N0 |
M0 |
|
IIA1 |
T2a1 |
N0 |
M0 |
|
IIA2 |
T2a2 |
N0 |
M0 |
|
IIB |
T2b |
N0 |
M0 |
|
III |
T3 |
N0 |
M0 |
|
IIIA |
T3a |
N0 |
M0 |
|
IIIB |
T1, T2, T3a |
N1 |
M0 |
|
|
T3B |
Any N |
M0 |
|
IVA |
T4 |
Any N |
M0 |
|
IVB |
Any T |
Any N |
M1 |
References
[868] Wittekind, C, TNM Klassifikation maligner Tumoren - Korrigierter Nachdruck 2020 mit allen Ergänzungen der UICC aus den Jahren 2017 bis 2019Wiley-VCH, Weinheim, 2020.